Preparation method of olaparib

By using SM-1 and SM-2 in the preparation of olapani, combined with inert gas protection and suitable catalysts, the problems of low safety and cumbersome operation in the prior art are solved, and high purity is achieved. High yield olapani preparation, suitable for industrial production.

CN119059981APending Publication Date: 2024-12-03SHANDONG NEW TIME PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310648583.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing Olapani preparation process has problems such as low safety, cumbersome operation, high production costs and unsuitable for industrial production, especially due to the use of toxic gas carbon monoxide and the operation of long-term reflow of sealing and pressurization.

Method used

Using SM-1 and SM-2 as raw materials, the reaction is carried out under the protection of inert gas, and the carbonylation reaction is carried out using catalysts such as Pd(OAc)2 and ligands to produce compound I-1, and then react with SM-3 to prepare O'O's Rapani, using mild reaction conditions and easy post-treatment steps, including filtration, washing and recrystallization, to improve product yield and purity.

Benefits of technology

The high purity and high yield preparation of olapani is achieved, the use of toxic gases is avoided, and the operation safety is improved, which is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004264216900000011
    Figure BDA0004264216900000011
  • Figure BDA0004264216900000012
    Figure BDA0004264216900000012
  • Figure BDA0004264216900000021
    Figure BDA0004264216900000021
Patent Text Reader

Abstract

The invention belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of olaparib. According to the method, 4-(3-bromine-4-fluorophenyl)-phenazine-1 (2H)-ketone is used as a starting material and reacts with trichlorophenyl formate under the action of a palladium catalyst and a ligand, and the obtained intermediate can continue to react with 1-cyclopropyl formyl piperidine without being purified to prepare olaparib. According to the method, the safety problem caused by the fact that carbon monoxide gas with high toxicity needs to be adopted when carbonylation reaction is carried out in the prior art is effectively solved; moreover, a target product can be prepared with high yield and high purity, and a safe and efficient process choice is provided for preparation of olaparib.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug synthesis, and particularly relates to a method for preparing olaparib. Background Art

[0002] Olaparib is a poly (ADP ribose) polymerase (PARP) inhibitor and the world's first PARP inhibitor drug to be marketed. Olaparib was first developed by the British company KuDOS. AstraZeneca acquired KuDOS in December 2005 and obtained its development rights. AstraZeneca's Olaparib capsules (trade name: Lynparza, specification: 50mg) were approved for marketing in the European Union on December 16, 2014, and were approved for marketing by the US FDA on December 19 of the same year. They are used to treat advanced ovarian cancer with BRCA1 / 2 gene mutations. They have significant efficacy, few adverse reactions, and good short-term tolerance in patients. On August 17, 2017, the US FDA approved the marketing of 100mg and 150mg olaparib tablets for the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. On January 12, 2018, the FDA approved Olaparib tablets for use in patients with breast cancer with gBRCA mutations. On September 20, 2018, the National Medical Products Administration (NMPA) approved the marketing of Olaparib tablets in the specifications of 100mg and 150mg in China. Its chemical structure is shown below:

[0003]

[0004] In 2014, Camille Lescot et al. reported a synthetic route of Olaparib in J.Am.Chem.Soc., 2014, 45, 6142-6147. The route involves the intermediate 4-(3-bromo-4-fluorophenyl)-phenolazine-1(2H)-one and 1-cyclopropylformylpiperidine in the presence of a palladium catalyst and carbon monoxide for carbonyl insertion reaction to obtain Olaparib crude product, which is then purified by column chromatography to prepare the target product. The synthetic route is as follows:

[0005]

[0006] However, the above process has the following problems: ① The carbonyl insertion reaction needs to be carried out using carbon monoxide, which is a toxic gas and has a high risk; ② Since the reaction is a gas-liquid two-phase reaction, it needs to be sealed and pressurized for a long time (100°C, 18h) to reflux, and the operation safety is relatively low; ③ The material 1-cyclopropylcarbonylpiperidine is greatly in excess during the reaction, resulting in a high production cost; ④ The acquisition of the target product requires cumbersome column chromatography operations, and can only be completed at the laboratory milligram level, which is not suitable for industrial scale-up production.

[0007] Patent CN108191769A uses phthalide and 3-bromo-4-fluorobenzaldehyde as starting materials, reacts under the action of sodium hydride to generate (Z)-3-(3-bromo-4-fluorobenzylidene)isobenzofuran-1(3H)-one, then reacts with hydrazine hydrate to obtain 4-(3-bromo-4-fluorophenyl)-phenoloxazine-1(2H)-one, and finally reacts with 1-cyclopropylformylpiperidine to obtain olaparib. The synthetic route is as follows:

[0008]

[0009] However, the carbonyl insertion reaction in the above route also uses carbon monoxide and needs to be carried out at 120°C. The operation safety is low and it is difficult to apply to industrial scale-up production.

[0010] In summary, given that the existing olaparib preparation process has many shortcomings in terms of process safety and cumbersome operation, it is still a problem that needs to be solved to find a reaction route suitable for the industrial production of olaparib with mild reaction conditions, simple operation process, high product yield and high purity. Summary of the invention

[0011] In view of the problems existing in the current preparation process of Olaparib, the present invention provides a method for preparing Olaparib. The target product prepared by the method has high purity and yield, and the reaction conditions are mild and the operation is safer.

[0012] The specific technical solutions of the present invention are as follows:

[0013] A method for preparing olaparib, characterized in that SM-1 and SM-2 are used as raw materials to react to obtain compound I-1, and compound I-1 is reacted with SM-3 to obtain olaparib, and the reaction route is as follows:

[0014]

[0015] Preferably, a method for preparing Olaparib comprises the following steps:

[0016] Step 1: Under the protection of inert gas, compound SM-1, catalyst, ligand, and base-1 are added to reaction solvent A, and after stirring evenly, a solution of compound SM-2 in solvent A is added at a controlled temperature of T1, and the reaction is continued at the same temperature until the reaction is completed to obtain compound I-1;

[0017] Step 2: Add compound I-1 and base-2 to solvent B, stir evenly, then add SM-3 and a solution of the catalyst in solvent B, control the temperature to T2 and react until the reaction is completed, and obtain Olaparib through post-treatment.

[0018] Preferably, the catalyst in step 1 is one of Pd(OAc)2 and PdCl2(PhCN)2, preferably Pd(OAc)2.

[0019] Preferably, the ligand in step 1 is one of P(t-Bu)3·HBF4, dppf (bis(diphenylphosphino)ferrocene), and Xantphos (4,5-bis(diphenylphosphine)-9,9-dimethylxanthene), preferably Xantphos.

[0020] Preferably, the base in step 1 is one of triethylamine, N,N-diisopropylethylamine and tri-n-butylamine, preferably triethylamine.

[0021] Preferably, in step 1, the molar ratio of compound SM-1 to compound SM-2 is 1:1.1 to 1.4, preferably 1:1.2.

[0022] Preferably, the molar ratio of the compound SM-1 to the catalyst, ligand, and base-1 in step 1 is 1: 1% to 8%: 2% to 16%: 1.5 to 3.0, preferably 1: 3.0%: 6%: 2.0.

[0023] Preferably, the reaction solvent A in step 1 is one of toluene, mesitylene, trifluorotoluene or a combination thereof, preferably toluene.

[0024] Preferably, the reaction temperature T1 in step 1 is 80-110°C, preferably 100-105°C.

[0025] Preferably, the inert gas in step 1 is one of argon and nitrogen, preferably argon.

[0026] In one embodiment, after the reaction in step 1 is completed, post-treatment is required, and the post-treatment steps are: filtering the reaction solution through a pad of diatomaceous earth, washing the filtrate with water and a saturated sodium chloride solution in turn, and concentrating to dryness under reduced pressure. The concentrate is recrystallized with n-hexane-ethyl acetate (3 to 5:1) to obtain compound I-1.

[0027] Preferably, the base-2 in step 2 is one of triethylamine, N,N-diisopropylethylamine, potassium carbonate and sodium carbonate, preferably triethylamine.

[0028] Preferably, the catalyst in step 2 is one of DMAP and PPY (4-pyrrolidinopyridine), preferably DMAP.

[0029] Preferably, the solvent B in step 2 is one of acetonitrile and tetrahydrofuran or a combination thereof, preferably tetrahydrofuran.

[0030] Preferably, in step 2, the molar ratio of compound I-1 to SM-3 is 1:1.2 to 2.0, preferably 1:1.5.

[0031] Preferably, the molar ratio of compound I-1 to base-2 and catalyst in step 2 is 1:1.5-2.5:2%-8%, preferably 1:2.0:5%.

[0032] Preferably, the reaction temperature T2 in step 2 is 30-60°C, preferably 40-45°C.

[0033] Preferably, the post-treatment step in step 2 comprises: filtering the reaction solution, concentrating the filtrate, adding an appropriate amount of organic solvent, washing with saturated brine, concentrating the organic phase to dryness under reduced pressure, and recrystallizing from ethyl acetate to obtain Olaparib. Preferably, the organic solvent is one of dichloromethane and chloroform or a combination thereof, preferably dichloromethane.

[0034] Beneficial effects of the present invention:

[0035] 1. The present invention provides a method for preparing Olaparib, wherein SM-1 is used as a starting material, after SM-2 is carbonylated to form an ester (I-1), the intermediate compound can be directly reacted with SM-3 without purification to obtain Olaparib.

[0036] 2. The present invention effectively solves the safety problem caused by the need to use highly toxic carbon monoxide gas during carbonylation reaction in the prior art.

[0037] 3. The preparation process of Olaparib of the present invention has mild reaction conditions and simple post-treatment operation, and the obtained product has high yield and purity, which is suitable for industrial production. DETAILED DESCRIPTION

[0038] The present invention is further illustrated by the following examples. It should be correctly understood that the examples of the present invention are only used to illustrate the present invention, rather than to limit the present invention. Therefore, simple improvements to the present invention based on the method of the present invention all fall within the scope of protection claimed by the present invention.

[0039] The structure of compound I-1 prepared by the present invention is confirmed as follows:

[0040] ESI-HRMS(m / z):476.9843, 478.9524[M+H] + ; 1H NMR(400MHz, DMSO-d6)δ:11.79(s,1H),8.23(dd,J=1.9,8.8Hz,1H),8.11(s,1H),7.98(dd,J=1.9,8.8Hz,1H),7.63(t d, J=1.9, 8.9Hz, 1H), 7.61 (td, J=1.9, 8.9Hz, 1H), 7.52~7.49 (m, 1H), 7.40 (s, 2H), 7.25 (t, J=9.1Hz, 1H), 3.70 (s, 2H).

[0041] The structure of Olaparib prepared by the present invention is confirmed as follows:

[0042] ESI-HRMS (m / z): 435.4328 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ: 12.56 (s, 1H), 8.26 (dd, J=0.9, 8.0Hz, 1H), 7.97 (d, J=7.5Hz, 1H), 7.90~7.94 (m, 1H), 7.85~7.89 (m, 1H), 7. 42~7.49(m,1H),7.36(d,J=5.5Hz,1H),7.22(t,J=9.0Hz,1H),4.30(s,2H),3.26~3.72(m,8H),1.97~1.99(m,1H),0.73~0.78(m,4H).

[0043] The present invention uses HPLC to determine the purity of Olaparib, and the chromatographic conditions are as follows:

[0044] Chromatographic column: YMC Triart--C 18 (4.6mm×250mm,5μm) or chromatographic column with equivalent performance;

[0045] Mobile phase: Mobile phase A: 0.05% trifluoroacetic acid / water; Mobile phase B: acetonitrile; Gradient elution (0min: A 85%, 15min: A 60%, 20min: 20%, 25min: 20%, 25.1min: A 85%, 30min: A 85%);

[0046] Column temperature: 35 °C;

[0047] Detection wavelength: 235nm;

[0048] Flow rate: 1.0ml / min;

[0049] Injection volume: 10 μl;

[0050] The retention time of Olaparib is about 12.7 minutes.

[0051] In the following embodiments, various processes and methods not described in detail are conventional methods known in the art.

[0052] Preparation of compound I-1:

[0053] Example 1

[0054] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.67 g, 3.0 mmol), Xantphos (3.47 g, 6.0 mmol), triethylamine (20.24 g, 0.2 mol) were added to toluene (200 ml), the temperature was controlled at 100-105 ° C, and a toluene (100 ml) solution of SM-2 (27.05 g, 0.12 mol) was added, and the temperature was continued to be controlled at 100-105 ° C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filtrate was washed with water (80 ml × 2), washed with saturated brine (80 ml), and the organic phase was concentrated to dryness under reduced pressure. After recrystallization with n-hexane-ethyl acetate (5:1), compound I-1 was obtained with a yield of 97.4% and a purity of 99.60%.

[0055] Example 2

[0056] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.67 g, 3.0 mmol), Xantphos (3.47 g, 6.0 mmol), triethylamine (20.24 g, 0.2 mol) were added to toluene (200 ml), the temperature was controlled at 100-105 ° C, SM-2 (31.56 g, 0.14 mol) in trifluorotoluene (100 ml) was added, and the temperature was continued to be controlled at 100-105 ° C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filtrate was washed with water (80 ml × 2), washed with saturated brine (80 ml), and the organic phase was concentrated to dryness under reduced pressure. After recrystallization with n-hexane-ethyl acetate (5:1), compound I-1 was obtained with a yield of 97.0% and a purity of 99.51%.

[0057] Example 3

[0058] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.67 g, 3.0 mmol), Xantphos (3.47 g, 6.0 mmol), triethylamine (20.24 g, 0.2 mol) were added to toluene (200 ml), and the temperature was controlled at 100-105 ° C. A solution of SM-2 (24.80 g, 0.11 mol) in trifluorotoluene (100 ml) was added, and the temperature was continued to be controlled at 100-105 ° C. The reaction was completed after detection, and the reaction solution was filtered through diatomaceous earth. The filtrate was washed with water (80 ml × 2) and saturated brine (80 ml). The organic phase was concentrated to dryness under reduced pressure and recrystallized from n-hexane-ethyl acetate (5:1) to obtain compound I-1 with a yield of 95.5% and a purity of 99.48%.

[0059] Example 4

[0060] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (1.78 g, 8.0 mmol), Xantphos (9.25 g, 16.0 mmol), triethylamine (20.24 g, 0.2 mol) were added to toluene (200 ml), and the temperature was controlled at 80-85 ° C. A solution of SM-2 (27.05 g, 0.12 mol) in toluene (100 ml) was added, and the temperature was continued to be controlled at 80-85 ° C. The reaction was completed after detection, and the reaction solution was filtered through diatomaceous earth. The filtrate was washed with water (80 ml × 2) and saturated brine (80 ml). The organic phase was concentrated to dryness under reduced pressure and recrystallized from n-hexane-ethyl acetate (5:1) to obtain compound I-1 with a yield of 96.3% and a purity of 99.52%.

[0061] Example 5

[0062] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (1.78 g, 8.0 mmol), Xantphos (1.16 g, 2.0 mmol), triethylamine (20.24 g, 0.2 mol) were added to toluene (200 ml), the temperature was controlled at 80-85 ° C, a toluene (100 ml) solution of SM-2 (27.05 g, 0.12 mol) was added, and the temperature was continued to be controlled at 80-85 ° C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filtrate was washed with water (80 ml × 2), washed with saturated brine (80 ml), and the organic phase was concentrated to dryness under reduced pressure. After recrystallization with n-hexane-ethyl acetate (5:1), compound I-1 was obtained with a yield of 93.7% and a purity of 99.34%.

[0063] Example 6

[0064] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.22 g, 1.0 mmol), Xantphos (1.16 g, 2.0 mmol), triethylamine (20.24 g, 0.2 mol) were added to toluene (200 ml), the temperature was controlled at 80-85 ° C, a toluene (100 ml) solution of SM-2 (27.05 g, 0.12 mol) was added, and the temperature was continued to be controlled at 80-85 ° C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filtrate was washed with water (80 ml × 2), washed with saturated brine (80 ml), and the organic phase was concentrated to dryness under reduced pressure. After recrystallization with n-hexane-ethyl acetate (5:1), compound I-1 was obtained with a yield of 92.5% and a purity of 99.30%.

[0065] Example 7

[0066] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.22 g, 1.0 mmol), Xantphos (9.25 g, 16.0 mmol), and triethylamine (20.24 g, 0.2 mol) were added to toluene (200 ml), and the temperature was controlled at 80-85 ° C. A solution of SM-2 (27.05 g, 0.12 mol) in toluene (100 ml) was added, and the temperature was continued to be controlled at 80-85 ° C. The reaction was completed after detection, and the reaction solution was filtered through diatomaceous earth. The filtrate was washed with water (80 ml × 2) and saturated brine (80 ml). The organic phase was concentrated to dryness under reduced pressure and recrystallized from n-hexane-ethyl acetate (5:1) to obtain compound I-1 with a yield of 93.2% and a purity of 99.33%.

[0067] Example 8

[0068] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.67 g, 3.0 mmol), Xantphos (3.47 g, 6.0 mmol), triethylamine (30.36 g, 0.3 mol) were added to toluene (200 ml), the temperature was controlled at 100-105 ° C, and a trifluorotoluene (100 ml) solution of SM-2 (31.56 g, 0.14 mol) was added, and the temperature was continued to be controlled at 100-105 ° C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filtrate was washed with water (80 ml × 2), washed with saturated brine (80 ml), and the organic phase was concentrated to dryness under reduced pressure. After recrystallization with n-hexane-ethyl acetate (3: 1), compound I-1 was obtained with a yield of 96.6% and a purity of 99.40%.

[0069] Example 9

[0070] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.67 g, 3.0 mmol), Xantphos (3.47 g, 6.0 mmol), triethylamine (15.18 g, 0.15 mol) were added to toluene (200 ml), the temperature was controlled at 100-105 ° C, and a trifluorotoluene (100 ml) solution of SM-2 (31.56 g, 0.14 mol) was added, and the temperature was continued to be controlled at 100-105 ° C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filtrate was washed with water (80 ml × 2), washed with saturated brine (80 ml), and the organic phase was concentrated to dryness under reduced pressure. After recrystallization with n-hexane-ethyl acetate (3:1), compound I-1 was obtained with a yield of 93.8% and a purity of 99.31%.

[0071] Example 10

[0072] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.67 g, 3.0 mmol), Xantphos (3.47 g, 6.0 mmol), triethylamine (10.12 g, 0.1 mol) were added to toluene (200 ml), the temperature was controlled at 100-105 ° C, and a solution of SM-2 (31.56 g, 0.14 mol) in trifluorotoluene (100 ml) was added. The temperature was continued to be controlled at 100-105 ° C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filtrate was washed with water (80 ml × 2), washed with saturated brine (80 ml), and the organic phase was concentrated to dryness under reduced pressure. After recrystallization with n-hexane-ethyl acetate (3:1), compound I-1 was obtained with a yield of 88.9% and a purity of 99.22%.

[0073] Embodiment 11

[0074] Under argon protection, SM-1 (33.32 g, 0.1 mol), PdCl2(PhCN)2 (1.15 g, 3.0 mmol), dppf (3.33 g, 6.0 mmol), N,N-diisopropylethylamine (38.78 g, 0.3 mol) were added to toluene (200 ml), and the temperature was controlled at 80-85 ° C. A solution of SM-2 (31.56 g, 0.14 mol) in mesitylene (100 ml) was added, and the temperature was continued to be controlled at 80-85 ° C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, and the filtrate was washed with water (80 ml × 2) and saturated brine (80 ml). The organic phase was concentrated to dryness under reduced pressure and recrystallized from n-hexane-ethyl acetate (3:1) to obtain compound I-1 with a yield of 94.5% and a purity of 99.46%.

[0075] Example 12

[0076] Under argon protection, SM-1 (33.32 g, 0.1 mol), PdCl2(PhCN)2 (1.15 g, 3.0 mmol), P(t-Bu)3·HBF4 (1.74 g, 6.0 mmol), tri-n-butylamine (55.60 g, 0.3 mol) were added to toluene (200 ml), and the temperature was controlled at 80-85°C. A solution of SM-2 (31.56 g, 0.14 mol) in mesitylene (100 ml) was added, and the temperature was continued to be controlled at 80-85°C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, and the filtrate was washed with water (80 ml×2) and saturated brine (80 ml). The organic phase was concentrated to dryness under reduced pressure and recrystallized from n-hexane-ethyl acetate (3:1) to obtain compound I-1 with a yield of 95.0% and a purity of 99.49%.

[0077] Preparation of Olaparib:

[0078] Embodiment 13

[0079] Compound I-1 (23.88 g, 0.05 mol) and triethylamine (10.12 g, 0.10 mol) were added to tetrahydrofuran (150 ml), stirred evenly, and then a solution of SM-3 (11.57 g, 0.075 mol) and DMAP (0.31 g, 2.50 mmol) in tetrahydrofuran (80 ml) was added. The temperature was controlled at 40-45°C to react. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and dichloromethane (150 ml) was added. Then, the mixture was washed with saturated brine (50 ml×2). The organic phase was concentrated to dryness under reduced pressure, and the concentrate was recrystallized from ethyl acetate to obtain Olaparib with a yield of 99.7% and a purity of 99.82%.

[0080] Embodiment 14

[0081] Compound I-1 (23.88 g, 0.05 mol) and triethylamine (10.12 g, 0.10 mol) were added to tetrahydrofuran (150 ml), stirred evenly, and then a solution of SM-3 (15.43 g, 0.1 mol) and DMAP (0.31 g, 2.50 mmol) in tetrahydrofuran (80 ml) was added. The temperature was controlled at 30-35°C to react. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and dichloromethane (150 ml) was added. The filtrate was then washed with saturated brine (50 ml×2). The organic phase was concentrated to dryness under reduced pressure, and the concentrate was recrystallized from ethyl acetate to obtain Olaparib with a yield of 99.0% and a purity of 99.81%.

[0082] Embodiment 15

[0083] Compound I-1 (23.88 g, 0.05 mol) and triethylamine (10.12 g, 0.10 mol) were added to tetrahydrofuran (150 ml), stirred evenly, and then a solution of SM-3 (9.26 g, 0.06 mol) and DMAP (0.31 g, 2.50 mmol) in tetrahydrofuran (80 ml) was added. The temperature was controlled at 30-35°C to react. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and dichloromethane (150 ml) was added. The filtrate was then washed with saturated brine (50 ml×2). The organic phase was concentrated to dryness under reduced pressure, and the concentrate was recrystallized from ethyl acetate to obtain Olaparib with a yield of 98.2% and a purity of 99.75%.

[0084] Example 16

[0085] Compound I-1 (23.88 g, 0.05 mol) and triethylamine (10.12 g, 0.10 mol) were added to acetonitrile (150 ml). After stirring, SM-3 (11.57 g, 0.075 mol) and DMAP (0.50 g, 4.0 mmol) in acetonitrile (80 ml) were added. The temperature was controlled at 40-45 °C to react. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and dichloromethane (150 ml) was added. Then, it was washed with saturated brine (50 ml×2). The organic phase was concentrated to dryness under reduced pressure. The concentrate was recrystallized from ethyl acetate to obtain Olaparib with a yield of 98.8% and a purity of 99.82%.

[0086] Embodiment 17

[0087] Compound I-1 (23.88 g, 0.05 mol) and triethylamine (10.12 g, 0.10 mol) were added to acetonitrile (150 ml). After stirring, SM-3 (11.57 g, 0.075 mol) and DMAP (0.12 g, 1.0 mmol) in acetonitrile (80 ml) were added. The temperature was controlled at 40-45 °C to react. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and dichloromethane (150 ml) was added. Then, it was washed with saturated brine (50 ml×2). The organic phase was concentrated to dryness under reduced pressure. The concentrate was recrystallized from ethyl acetate to obtain Olaparib with a yield of 97.0% and a purity of 99.73%.

[0088] Embodiment 18

[0089] Compound I-1 (23.88 g, 0.05 mol) and potassium carbonate (17.27 g, 0.125 mol) were added to acetonitrile (150 ml). After stirring, SM-3 (11.57 g, 0.075 mol) and DMAP (0.50 g, 4.0 mmol) in acetonitrile (80 ml) were added. The temperature was controlled at 40-45°C to react. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and dichloromethane (150 ml) was added. Then, it was washed with saturated brine (50 ml×2). The organic phase was concentrated to dryness under reduced pressure. The concentrate was recrystallized from ethyl acetate to obtain Olaparib with a yield of 98.1% and a purity of 99.71%.

[0090] Embodiment 19

[0091] Compound I-1 (23.88 g, 0.05 mol) and N,N-diisopropylethylamine (9.69 g, 0.075 mol) were added to acetonitrile (150 ml). After stirring, SM-3 (11.57 g, 0.075 mol) and DMAP (0.50 g, 4.0 mmol) in acetonitrile (80 ml) were added. The temperature was controlled at 40-45 ° C. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and dichloromethane (150 ml) was added. Then, it was washed with saturated brine (50 ml×2). The organic phase was concentrated to dryness under reduced pressure, and the concentrate was recrystallized from ethyl acetate to obtain Olaparib with a yield of 97.4% and a purity of 99.70%.

[0092] Embodiment 20

[0093] Compound I-1 (23.88 g, 0.05 mol) and triethylamine (10.12 g, 0.10 mol) were added to acetonitrile (150 ml). After stirring, a solution of SM-3 (11.57 g, 0.075 mol) and PPY (0.60 g, 4.0 mmol) in acetonitrile (80 ml) was added. The reaction was controlled at 60°C. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and added with dichloromethane (150 ml). The filtrate was then washed with saturated brine (50 ml×2). The organic phase was concentrated to dryness under reduced pressure. The concentrate was recrystallized from ethyl acetate to obtain Olaparib with a yield of 96.8% and a purity of 99.77%.

[0094] Embodiment 21

[0095] Under argon protection, SM-1 (33.32 g, 0.1 mol), Pd(OAc)2 (0.67 g, 3.0 mmol), Xantphos (3.47 g, 6.0 mmol), triethylamine (20.24 g, 0.2 mol) were added to toluene (200 ml), and the temperature was controlled at 100-105°C. A toluene (100 ml) solution of SM-2 (27.05 g, 0.12 mol) was added, and the temperature was continued to be controlled at 100-105°C. After the reaction was completed, the reaction solution was filtered through diatomaceous earth and the filtrate was concentrated.

[0096] The concentrate (0.1 mol) and triethylamine (20.24 g, 0.20 mol) were added to tetrahydrofuran (300 ml), and after stirring, a solution of SM-3 (23.14 g, 0.15 mol) and DMAP (0.62 g, 5.0 mmol) in tetrahydrofuran (160 ml) was added, and the temperature was controlled at 40-45° C. to react. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and dichloromethane (300 ml) was added, and then washed with saturated brine (100 ml×2). The organic phase was concentrated to dryness under reduced pressure, and the concentrate was recrystallized from ethyl acetate to obtain Olaparib with a total yield of 97.0% and a purity of 99.75%.

Claims

1. A method for preparing Olaparib, characterized in that: SM-1 and SM-2 are used as raw materials to react to obtain compound I-1, and compound I-1 reacts with SM-3 to obtain Olaparib. The reaction route is as follows:

2. The preparation method according to claim 1, characterized in that: The specific steps include: Step 1: Under the protection of inert gas, compound SM-1, catalyst, ligand, and base-1 are added to reaction solvent A, and after stirring evenly, a solution of compound SM-2 in solvent A is added at a controlled temperature of T1, and the reaction is continued at the same temperature until the reaction is completed to obtain compound I-1; Step 2: Add compound I-1 and base-2 to solvent B, stir evenly, then add SM-3 and a solution of the catalyst in solvent B, control the temperature to T2 and react until the reaction is completed, and obtain Olaparib through post-treatment.

3. The preparation method according to claim 2, characterized in that: The catalyst in step 1 is one of Pd(OAc)2 and PdCl2(PhCN)2, preferably Pd(OAc)2; the ligand in step 1 is one of P(t-Bu)3·HBF4, dppf, and Xantphos, preferably Xantphos.

4. The preparation method according to claim 2, characterized in that: In step 1, the base is one of triethylamine, N,N-diisopropylethylamine, and tri-n-butylamine, preferably triethylamine; the reaction solvent A is one of toluene, mesitylene, and trifluorotoluene, or a combination thereof, preferably toluene.

5. The preparation method according to claim 2, characterized in that: In step 1, the molar ratio of compound SM-1 to compound SM-2 is 1:1.1-1.4; the molar ratio of compound SM-1 to catalyst, ligand, and base-1 is 1:1%-8%:2%-16%:1.5-3.0, preferably 1:3.0%:6%:2.

0.

6. The preparation method according to claim 2, characterized in that: The reaction temperature T1 in step 1 is 80-110°C, preferably 100-105°C; the reaction temperature T2 in step 2 is 30-60°C, preferably 40-45°C.

7. The preparation method according to claim 2, characterized in that: The base-2 in step 2 is one of triethylamine, N,N-diisopropylethylamine, potassium carbonate, and sodium carbonate; the solvent B in step 2 is one of acetonitrile and tetrahydrofuran, or a combination thereof.

8. The preparation method according to claim 2, characterized in that: The catalyst in step 2 is one of DMAP and PPY, preferably DMAP.

9. The preparation method according to claim 2, characterized in that: The molar ratio of compound I-1 to SM-3 in step 2 is 1:1.2-2.0, preferably 1:1.5; the molar ratio of compound I-1 to base-2 and catalyst in step 2 is 1:1.5-2.5:2%-8%, preferably 1:2.0:5%.

10. The preparation method according to claim 2, characterized in that: The specific steps of the post-treatment in step 2 include: filtering the reaction solution, concentrating the filtrate, adding an appropriate amount of organic solvent, washing with saturated brine, concentrating the organic phase to dryness under reduced pressure, and recrystallizing with ethyl acetate to obtain Olaparib.